REGN vs BMRN vs ALNY vs BEAM

For growth investors, Beam Therapeutics Inc.

(BEAM) is the stronger pick with 120. 0% revenue growth year-over-year, versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 17. 1x trailing P/E (15. 3x forward), making it the more compelling value choice. Analysts rate Regeneron Pharmaceuticals, Inc. (REGN) a "Buy" — based on 48 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Regeneron Pharmaceuticals, Inc.

(REGN) is the cheapest at 17. 1x versus Alnylam Pharmaceuticals, Inc. at 127. 0x. On forward P/E, BioMarin Pharmaceutical Inc. is actually cheaper at 12. 6x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Alnylam Pharmaceuticals, Inc.

(ALNY) delivered a total return of +125. 4%, compared to -55. 6% for Beam Therapeutics Inc. (BEAM). Over 10 years, the gap is even starker: ALNY returned +411. 9% versus BMRN's -35. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), BioMarin Pharmaceutical Inc.

(BMRN) is the lower-risk stock at 0. 65β versus Beam Therapeutics Inc. 's 2. 14β — meaning BEAM is approximately 229% more volatile than BMRN relative to the S&P 500. On balance sheet safety, Regeneron Pharmaceuticals, Inc. (REGN) carries a lower debt/equity ratio of 9% versus 162% for Alnylam Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Beam Therapeutics Inc.

(BEAM) is pulling ahead at 120. 0% versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). On earnings-per-share growth, the picture is similar: Alnylam Pharmaceuticals, Inc. grew EPS 206. 9% year-over-year, compared to -18. 6% for BioMarin Pharmaceutical Inc.. Over a 3-year CAGR, ALNY leads at 53. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Regeneron Pharmaceuticals, Inc.

(REGN) is the more profitable company, earning 31. 4% net margin versus -57. 2% for Beam Therapeutics Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 24. 9% versus -274. 6% for BEAM. At the gross margin level — before operating expenses — REGN leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, BioMarin Pharmaceutical Inc.

(BMRN) trades at 12. 6x forward P/E versus 44. 2x for Alnylam Pharmaceuticals, Inc. — 31. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BMRN: 65. 6% to $89. 64.

In this comparison, REGN (0.

5% yield) pays a dividend. BMRN, ALNY, BEAM do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Alnylam Pharmaceuticals, Inc.

(ALNY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 71), +411. 9% 10Y return). Beam Therapeutics Inc. (BEAM) carries a higher beta of 2. 14 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALNY: +411. 9%, BEAM: +67. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: REGN is a mid-cap deep-value stock; BMRN is a mid-cap quality compounder stock; ALNY is a mid-cap high-growth stock; BEAM is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.